GlassScriptPhysician profile
Jason R Lorch
NPI 1649265109
$2,499.09
in general payments reported to CMS, 2019-2025
31 companies · $158 in 2025
The $158 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $212 · 2020: $257 · 2021: $625 · 2022: $592 · 2023: $383 · 2024: $271 · 2025: $158.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $812.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $812.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $394.45 | 2019-2024 | |
| Novo Nordisk INC | $312.32 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Janssen Pharmaceuticals, INC | $276.84 | 2020-2023 | Xarelto |
| Amgen INC. | $213.45 | 2019-2024 | Repatha, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $172.78 | 2020-2025 | Jardiance |
| Abbott Laboratories | $125.53 | 2020-2021 | |
| Lilly USA, LLC | $116.78 | 2020-2023 | Mounjaro |
| Medtronic, INC. | $98.32 | 2022-2025 | Inceptiv, Minimed 780g |
| Astrazeneca Pharmaceuticals LP | $96.07 | 2020-2025 | Airsupra |
| Insulet Corporation | $60.88 | 2023-2024 | Omnipod |
| Dexcom, INC. | $58.30 | 2021-2023 | Dexcom G6 Transmitter |
| Idorsia Pharmaceuticals US INC | $55.44 | 2022-2023 | Quviviq |
| Glaxosmithkline, LLC. | $47.18 | 2020-2023 | Trelegy Ellipta |
| Inari Medical, INC. | $43.41 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Sanofi-Aventis U.S. LLC | $41.16 | 2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $37.49 | 2019 | |
| Philips North America LLC | $35.20 | 2021-2024 | (Ck4) Mcot |
| Antares Pharma, INC. | $32.36 | 2019 | |
| Exact Sciences Corporation | $32.23 | 2023 | Cologuard Collection Kit |
| Phathom Pharmaceuticals, INC. | $29.88 | 2024 | Voquezna |
| Biohaven Pharmaceutical Holding Company LTD. | $29.34 | 2022 | |
| Amarin Pharma, INC. | $27.87 | 2021-2022 | |
| Pfizer INC. | $24.92 | 2019 | |
| Genentech USA, INC. | $24.08 | 2021 | |
| Allergan, INC. | $22.47 | 2020 | |
| Supernus Pharmaceuticals, INC. | $19.26 | 2023 | Qelbree |
| Biohaven Pharmaceuticals, INC. | $18.00 | 2021 | |
| Shire North American Group INC | $16.56 | 2019 | |
| Inspire Medical Systems, INC. | $12.91 | 2023 | Inspire |
| Upsher-Smith Laboratories LLC | $12.24 | 2019 | |
| Merck Sharp & Dohme LLC | $11.37 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Lorch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.